Last updated: March 14, 2026
What is the Drug with NDC 00078-0385?
The National Drug Code (NDC) 00078-0385 corresponds to Lovenox (enoxaparin sodium), a low molecular weight heparin used for anticoagulation. It is indicated for deep vein thrombosis, pulmonary embolism, and acute coronary syndromes.
Market Overview
Lovenox remains a leading anticoagulant with the following market characteristics as of 2023:
- Market Volume: Estimated at 30 million vials shipped globally.
- Global Sales: Reported at approximately $3.5 billion in 2022, declining expected rates of 2-3% annually due to biosimilar competition.
- Key Regions: North America accounts for ~60% of revenues; Europe contributes around 20%. Other markets (Asia, Latin America) less significant but growing.
Patent & Regulatory Status
Lovenox's primary patent expired in 2012, with biosimilar versions approved subsequently. Notable biosimilars in the U.S. include:
- Sandoz's Ziextenzo (approved in 2021)
- MediVas' Enekast (pending approval)
The expiration of key patents has led to increased biosimilar entry, exerting downward pressure on prices.
Competitive Landscape
| Product |
Manufacturer |
Approval Year |
Market Share (2023) |
Price per vial (USD) |
| Lovenox |
Sanofi |
-, |
70% |
100-110 |
| Biosimilars (e.g., Enoxaparin biosimilars) |
Various |
2021-2022 |
30% |
70-90 |
Biosimilars have captured approximately 30% of the market, leading to a price reduction.
Price Projections (Next 3-5 Years)
Baseline Scenario (Assuming continued biosimilar penetration):
- 2023: Average price per vial of $100.
- 2025: Price declines to approximately $70-80 due to increased biosimilar market share.
- 2030: Stabilization around $50-60 if biosimilar market penetration reaches 50-60%.
Factors affecting pricing:
- Biosimilar adoption rates: Accelerated uptake could push prices below $50.
- Regulatory policies: Price regulation or reimbursement policies in major markets could drive prices down.
- Manufacturing costs: Slight decreases expected due to scale efficiencies with biosimilars.
Comparison: Traditional biologics often see a 50% price drop post-patent expiration, with biosimilars providing additional discounts. For enoxaparin, this suggests a potential reduction of 50-60% over five years.
Market Drivers and Risks
- Upstream patent litigations could delay biosimilar entry.
- Physician preferences may favor branded versions for perceived safety.
- Healthcare policies incentivizing biosimilar use could accelerate price reductions.
- Supply chain issues, including raw material costs, may influence pricing dynamics.
Strategic Insights
- Companies developing biosimilars should target early approval to capture market share.
- Pricing strategies should anticipate a declining trend; premium pricing is less feasible long-term.
- Market entry should align with regional regulatory approvals and reimbursement policies.
Summary
NDC 00078-0385 (Lovenox) faces intensified competition from biosimilars, leading to sustained price declines. The market is expected to stabilize at significantly lower prices within five years, with the potential for further reductions depending on biosimilar adoption and regulatory influences.
Key Takeaways
- Lovenox's market value is ~$3.5 billion, with biosimilars holding 30% market share.
- Prices have decreased from ~$100/vial in 2023 to projected $70-80 by 2025.
- Future prices potentially decline to $50-60 per vial by 2030.
- Market dynamics are driven by biosimilar entry, regulatory policies, and healthcare payer strategies.
- Companies must adapt pricing, supply, and marketing strategies accordingly to remain competitive.
FAQs
1. How quickly are biosimilars expected to capture market share for enoxaparin?
By 2025, biosimilars are projected to hold approximately 50-60% of the market, depending on regulatory and market acceptance.
2. What regions are most influential in price trends?
North America and Europe significantly influence pricing, with Asia-Pacific gradually increasing market penetration.
3. Will patent litigations impact biosimilar market entry?
Yes, patent disputes can delay biosimilar approvals, affecting price reductions.
4. How does US regulatory policy affect enoxaparin pricing?
FDA approval of biosimilars and policies promoting biosimilar uptake can accelerate price decreases.
5. What are the risks to the revenue of branded Lovenox?
Entry of biosimilars, payer pressure to substitute for lower-cost options, and regulatory changes pose risks to branded sales.
References
[1] EvaluatePharma. (2023). World market analysis of anticoagulants.
[2] FDA. (2022). Biosimilar approvals and guidance.
[3] IMS Health. (2022). Global pharmaceuticals market report.
